Although Oklahoma is fortunate to have a cadre of basic science investigators who receive federal and national support, we lag behind in our potential in generating well-funded programs in clinical and translational research. The FOA backs this in its statement that """"""""tremendous challenges and opportunities remain for pursuing activities aligned with the NIH's growing interest and focus on clinical and translational research"""""""" in IDeA states. Given the disparities that exist in the infrastructure, it is imperative that innovative new strategies are designed to help investigators from Oklahoma and other IDeA states to compete successfully for National and Federal Funding. To achieve these goals, it is necessary to create an environment that facilitates the expansion and acceleration of our clinical and translational research programs, focusing our efforts on the issues which remain the major health challenges to our state, to our OSCTR IDeA partner states and our underserved communities with health disparities. As such, our emphasis will be on clinical and translational research focused on diabetes, accelerated heart disease, obesity, cancer, arthritis, autoimmunity and issues important to childhood health. Our long-term goal is to improve our existing infrastructure and to provide the tools that investigators throughout Oklahoma and collaborating IDeA states need to attract new research dollars to the region from outside sources to support innovative and collaborative research programs. These funds are crucial to help address health issues and health disparities, which are major challenges for IDeA states. Our major objective is to establish a program that will provide the necessary infrastructure to support a clinical and translational pilot grant program. Our central hypothesis is that by providing early support in the form of strategic leadership, grant funding, and mentorship to investigators with meritorious projects, we will identify and train a new generation of well-trained, well-funded investigators who will be more readily equipped to translate scientific discoveries into practical applications.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1-TWD-C (CC))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Oklahoma Health Sciences Center
Oklahoma City
United States
Zip Code
Rostaminia, Ghazaleh; Peck, Jennifer D; Quiroz, Lieschen H et al. (2016) Characteristics associated with pelvic organ prolapse in women with significant levator ani muscle deficiency. Int Urogynecol J 27:261-7
Munroe, Melissa E; Young, Kendra A; Kamen, Diane L et al. (2016) Soluble Mediators and Clinical Features Discern Risk of Transitioning to Classified Disease in Relatives of Systemic Lupus Erythematosus Patients. Arthritis Rheumatol :
Sandhya, Pulukool; Kurien, Biji Theyilamannil; Danda, Debashish et al. (2016) Update on Pathogenesis of Sjögren's syndrome. Curr Rheumatol Rev :
Rabadi, Meheroz H; Aston, Christopher E (2016) Compare serum creatinine versus Renal (99m)Tc-DTPA scan determined glomerular filtration rates in veterans with traumatic spinal cord injury and meurogenic bladder. J Spinal Cord Med 39:638-644
Young, Kendra A; Munroe, Melissa E; Guthridge, Joel M et al. (2016) Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus. Ann Rheum Dis :
Hannafon, Bethany N; Trigoso, Yvonne D; Calloway, Cameron L et al. (2016) Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res 18:90
Heu, May Kou; Welborn, Toney; Nagykaldi, Zsolt (2016) Clinical Question: In adult patients on warfarin, does-home-self-testing of prothrombin time and/or international normalized ratio provide the same outcomes compared to testing by a home health nurse or in a clinical setting? J Okla State Med Assoc 109:99-100
Wolska, Nina; Rybakowska, Paulina; Rasmussen, Astrid et al. (2016) Brief Report: Patients With Primary Sjögren's Syndrome Who Are Positive for Autoantibodies to Tripartite Motif-Containing Protein 38 Show Greater Disease Severity. Arthritis Rheumatol 68:724-9
Lu, Rufei; Munroe, Melissa E; Guthridge, Joel M et al. (2016) Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J Autoimmun 74:182-193
Bonney, Phillip A; Maurer, Adrian J; Cheema, Ahmed A et al. (2016) Clinical significance of changes in pB-C2 distance in patients with Chiari Type I malformations following posterior fossa decompression: a single-institution experience. J Neurosurg Pediatr 17:336-42

Showing the most recent 10 out of 134 publications